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Introduction {#sec001}
============

Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease characterized by wax and wane inflammation. The prevalence of IBD is gradually increasing in Korea as well as in western countries \[[@pone.0225739.ref001]--[@pone.0225739.ref003]\]. The pathogenesis of IBD is not clearly understood. However, it is generally agreed that genetic factors, environmental factors, and immunoregulatory factors such as excessive immune reaction to the intestinal microbiome are involved \[[@pone.0225739.ref004], [@pone.0225739.ref005]\]. For the treatment of IBD, biological, anti-cytokine, and anti-adhesion molecule medications are being developed in addition to conventional therapies that include 5-aminosalicylic acid, corticosteroids, and immunomodulators. However, treatment outcome is less than ideal in 20 to 30% of patients \[[@pone.0225739.ref006], [@pone.0225739.ref007]\]. Recently stem cell therapy has been recognized as a potential new therapeutic method for such intractable diseases \[[@pone.0225739.ref008]\].

Mesenchymal stem cells (MSC) are present in various types of tissues. They are pluripotent and can differentiate to many kinds of mesodermal cells such as adipocytes, chondrocytes, and osteocytes \[[@pone.0225739.ref009]--[@pone.0225739.ref012]\]. There have been many attempts to use MSC for the treatment of many types of diseases, based on their ability to suppress immunocyte proliferation and to control inflammation, because of their secretion of various cytokines \[[@pone.0225739.ref009], [@pone.0225739.ref013]\]. A number of human and animal studies have demonstrated the anti-inflammatory effects of MSC in IBD \[[@pone.0225739.ref008], [@pone.0225739.ref014], [@pone.0225739.ref015]\].

Bone marrow and adipose tissues are major sources of MSC. Recently, tonsil-derived mesenchymal stem cells (TMSC) were reported to have characteristics of MSC \[[@pone.0225739.ref016]--[@pone.0225739.ref018]\]. TMSC has several advantages compared with other MSC. They are easily acquired from resected and discarded tissues after tonsillectomy, a commonly performed surgical procedure in children, and the doubling time of TMSC is short, possibly owing to the young age of the donor. Secondly, TMSC acquired from many donors tend to unify and grow well without the domination by a certain cell line, and have pronounced differentiation capacity and immune modulatory activity \[[@pone.0225739.ref017]\]. In addition, the characteristics of stem cells are well conserved and are not, damaged after freezing and de-freezing. Therefore, TMSC may serve as a source for future stem cell banks and may also be easily used clinically.

In our previous studies, the intraperitoneal (IP) administration of TMSC in dextran sulfate sodium (DSS)-induced acute and chronic colitis animal models demonstrated improvements in disease activity index (DAI), colon length, and the expression of pro-inflammatory cytokines \[[@pone.0225739.ref019], [@pone.0225739.ref020]\]. To trace the localization of the TMSC *in vivo*, TMSC tagged with PKH26 red fluorescent cell linker were administered to normal mice and mice with acute colitis. Fluorescence microscopy examination of the colon tissues acquired after 5 days did not reveal any red TMSC-PKH26 cells \[[@pone.0225739.ref019]\]. Therefore, it was presumed that the TMSC did not migrate directly to the inflammation site of the intestine, with the results explained by the paracrine effect of the TMSC.

This study aimed to evaluate the therapeutic effect of the conditioned medium (CM) released by TMSC (TMSC-CM) in DSS-induced chronic murine colitis models. TMSC-CM is more feasible for preparation and application than TMSC themselves. We hypothesized that TMSC-CM will exert therapeutic effects similar to those of TMSC upon IP administration.

Materials and methods {#sec002}
=====================

Isolation of TMSC {#sec003}
-----------------

TMSC developed in 'Ewha Tonsil-derived Mesenchymal Stem Cell Research Center (ETSRC)' were used. The tonsil tissue was acquired from the patients who agreed to provide resected tissues from their tonsillectomy surgeries after informed consent. The process was approved by the Institutional Review Board of Ewha Womans University Mokdong Hospital (ECT 11-53-02). The palatine tonsil tissue was acquired immediately after surgery and washed 5 times with phosphate buffered saline (PBS), followed by being minced. They were then digested for 30 min at 37°C in a Roswell Park Memorial Institute 1640 (RPMI-1640) medium (Invitrogen, Carlsbad, CA, USA) with 210 U/mL collagenase type 1 (Invitrogen) and 10 μg/mL DNase (Sigma-Aldrich, St. Louis, MO, USA). After being passed through a cell strainer, the cells were washed twice with 20% human serum and 10% human serum in RPMI 1640 medium. Monocytes were isolated by Ficoll-Paque (GE Healthcare, Buckinghamshire, UK) density gradient centrifugation. The cells were cultured in low-glucose Dulbecco's modified Eagle's medium (DMEM) (Welgene, Daegu, South Korea) containing antibiotics and 10% heat-inactivated fetal bovine serum (FBS) (Capricorn, Ebsdorfergrund, Germany), until they attained a cell density of 5×10^5^ cells/well, and non-adherent cells were removed after 24 h. TMSC of passage 5--7 were used for the experiment.

Preparation of TMSC conditioned medium {#sec004}
--------------------------------------

TMSC conditioned medium (TMSC-CM) was acquired after seeding 5×10^5^ TMSC (in 10ml low-glucose DMEM containing 10% FBS) in a 100 mm dish, harvesting the cells for 5--7 days (total 2×10^6^ cells), and removing the cell debris by centrifugation at 3,800 ×*g* for 5 min at 4°C. The medium was then collected, filtered through a 0.2 μm filter, and then stored at 4°C.

TMSC-CM was triple-concentrated (TMSC-CM-conc) using a 100 kDa cut-off centrifugal filter (Amicon Ultra, Merck Millipore, Burlington, MA, USA) at 3,800 ×*g* for 5 min at 4°C, and the medium that was heavier than 100 kDa was collected from the upper tube.

*In vitro* immunosuppression assay {#sec005}
----------------------------------

Immunosuppressive effects of TMSC-CM were confirmed by splenocyte immunosuppression assay. Splenocyte isolation (1×10^6^ cells) was performed from the spleen of a C57BL/6 mouse. Splenocytes were stimulated with the following mitogens; 5 μg/mL of lipopolysaccharide (LPS) (Sigma-Aldrich) for B-cell activation, or 20 ng/mL of phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) plus 1 μg/mL of ionomycin (Sigma-Aldrich) for T-cell activation. The activated splenocytes were cultured in TMSC-CM or TMSC-CM-conc, or co-cultured with TMSC for 24 h. After 24 h, proliferation of splenocytes was measured with an ELISA reader, using the Cell Counting Kit (CCK)-8 assay kit (Dojindo Molecular Technologies, Rockville, MD, USA) at 450 nm.

Analysis of the TMSC-CM components {#sec006}
----------------------------------

To identify proteins from the CM, 1 mL of the basal medium, low-glucose DMEM (10% FBS), and 1 mL of the TMSC-CM were each loaded onto cytokine and angiogenesis array membrane (R&D systems, Inc., Minneapolis, Minnesota, USA). After blocking the array membrane with blocking buffer for 1 h and membrane washing, the TMSC-CM and array detection antibody cocktail was mixed and added to the blocked membrane followed by overnight shaking incubation at 4°C. After washing, streptavidin-HRP buffer was added to the membrane, and incubation was performed for 30 min. Following another washing, Chemi Reagent Mixture was added to the membrane for reaction at room temperature for 1 min and measured using LAS-300 system (Fujifilm, Tokyo, Japan). Dot density was analyzed using Multi Gauge 3.0 software. Anti-inflammatory and pro-inflammatory cytokine levels were measured using cytokine array, and growth factor levels were measured using angiogenesis array.

Development of a chronic colitis mouse model {#sec007}
--------------------------------------------

The animal models used for the experiment were seven-week-old C57BL/6 male mice (Orient Bio Co., Ltd., Sungnam, Gyeonggi, Korea) with an average weight of 20--22 g. The mice were allowed 7 days of adaptation period at the facility of the Ewha Womans University Medical Research Institute prior to the experiment. The environment was set to standardized environment for study animals. Day time and night time were provided at 12 h intervals, and temperature (23 ± 2°C) and humidity (45--55%) were set to appropriate levels. This study was approved by the Ethics Committee for Animal Research of Ewha Womans University (ESM 15--0312).

Chronic colitis was induced by oral administration of 1.5% DSS (molecular weight 36 ± 50 kDa, MP biochemical, Irvine, CA, USA) for 5 days continuously followed by an additional 5 days of tap water feeding; a total of 3 such cycles (total 30 days) was performed.

*In vivo* experimental design {#sec008}
-----------------------------

Mice were randomly assigned into 5 groups: 1) the normal control, 2) colitis control, 3) TMSC injection, 4) TMSC-CM injection, and 5) TMSC-CM-conc injection groups.

Normal control group mice were provided with standardized water and food without any pre-treatment. In the colitis control group and three other treatment groups, chronic colitis was induced with 1.5% DSS. For the colitis control group, PBS was IP injected to match the effect of cell administration-related stress with the TMSC group. Mice in the colitis control group received four IP injections of 500 μL of PBS, those in the TMSC group received four IP injections of 1×10^6^TMSC/500 μL. The TMSC-CM group received 12 IP injections of 500 μL of TMSC-CM (equivalent to 1×10^5^ TMSC) in order to match the amount of TMSC with the TMSC group. As the number of injections increases, the injection-related stress of the mouse increases, therefore, the same number of injections could be used to reduce the bias. The TMSC-CM-conc group, which received four IP injection of 500 μL of TMSC-CM-conc (equivalent to 3×10^5^ TMSC), was designed in order to match the number of injections with that of the TMSC group ([Fig 1](#pone.0225739.g001){ref-type="fig"}).

![Experimental design.\
Mice were randomly assigned into 5 groups: the normal control, colitis control, TMSC injection, TMSC-CM injection, TMSC-CM-conc injection groups. Mice in the colitis control group received 4 IP injections of PBS, those in the TMSC group received 4 IP injections of TMSC, those in the TMSC-CM group received 12 IP injections of TMSC-CM, and those in the TMSC-CM-conc group received 4 IP injections of triple-concentrated TMSC-CM. DSS, dextran sulfate sodium; PBS, phosphate buffered saline.](pone.0225739.g001){#pone.0225739.g001}

Assessment of the effect of TMSC and TMSC-CM {#sec009}
--------------------------------------------

The severity of colitis in each mouse was assessed by measuring their DAI, body weight change, colon length, histologic grading, and cytokine levels. For each group, weight change, stool consistency, and occult or grossly observed blood from stool or anus were checked daily and the DAI was assessed ([S1 Table](#pone.0225739.s001){ref-type="supplementary-material"}) \[[@pone.0225739.ref021]\]. On day 31 of the experiment, mice were sacrificed with CO~2~ inhalation, and colon specimens were acquired from the proximal and distal parts of the dissected colon and fixed with 10% formalin, followed by paraffin sectioning and hematoxylin-eosin (H&E) staining. Two specimens from each proximal and distal colon were analyzed using a previously reported histologic colitis scoring system ([S2 Table](#pone.0225739.s002){ref-type="supplementary-material"}) \[[@pone.0225739.ref022]\].

The colon specimen was frozen to -70°C in the cryogenic freezer until analysis. One milliliter of TRIzol Reagent (Ambion, Life Technologies, Carlsbad, CA, USA) was added to the colon specimen, and after being minced, 200 μL of chloroform (Sigma) was added, followed by vortexing. After leaving the sample at the room temperature for 2 to 3 min, it was centrifuged at 13,000 ×*g* (4°C) for 10 min. The supernatants were added into a new tube and the same amount of isopropanol (Sigma) was added; after mixing by inversion, the sample was left at room temperature for 5 min, and then centrifuged again at 13,000 ×*g* (4°C) for 10 min. The cell pellet was washed with 75% ethanol for 2--3 times and dried at room temperature. Nuclease-free water was then added, and the RNA concentration was measured with Nabi (nano-drop) (Micro Digital, Korea). Then, 2 μg of RNA and 0.5 μg of oligo dT primer were mixed, and the sample was left at 70°C for 10 min. Next, 200 units of Molony Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Promega, Fitchburg, WI, USA), 25 units of rRNasin Ribonuclase inhibitor (Promega), 5 X RT buffer and 2 mM of dNTP were added, and the final volume was set to 25 μL by adding an appropriate amount of nuclease-free water. They were treated at 42°C for 60 min, and 95°C for 5 min, and then stored at 4°C. Quantstudio 3 real-time polymerase chain reaction (PCR) system (Applied Biosystems, Waltham, MA, USA) was used for analysis, using 0.1 μg of the synthesized cDNA as a template for the 2X Power SYBR Green PCR Master mix (Applied Biosystems) and each primer set. The primers used in this study were made by Macrogen (Korea). Pro-inflammatory cytokines, interleukin (IL)-1β, IL-6, tumor necrosis factor α (TNFα), IL-17, and the anti-inflammatory cytokine IL-10 levels were measured; each primer sequence is shown in [Table 1](#pone.0225739.t001){ref-type="table"}. Each PCR was performed after 10 min of pre-denaturation at 95°C, 15 seconds at 95°C and 1 min at 60°C; this was repeated 40 times. After the PCR was complete, a melting curve was drawn to check the accuracy of gene amplification. For the internal compensation of gene expression level, the house keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was also used, and relative gene expression levels were presented as 2^-ΔΔCt^ values.

10.1371/journal.pone.0225739.t001

###### Primer sequences of the Reverse Transcription Polymerase Chain Reaction (real time-PCR).

![](pone.0225739.t001){#pone.0225739.t001g}

  Primer             Sequence
  -------- --------- -----------------------------------
  IL-1β    Forward   `5'-GAGCCCATCCTCTGTGACTC-3'`
           Reverse   `5'-TCCATTGAGGTGGAGAGCTT-3'`
  IL-6     Forward   `5’-CCGGAGAGGAGACTTCACAG-3’`
           Reverse   `5’-TCCACGATTTCCCAGAGAAC-3’`
  IL-17    Forward   `5'-TCCCTCTGTGATCTGGGAAG-3'`
           Reverse   `5'-CTCGACCCTGAAAGTGAAGG-3'`
  TNFα     Forward   `5’-ACGGCATGGATCTCAAAGAC-3’`
           Reverse   `5’-AGATAGCAAATCGGCTGACG-3’`
  GAPDH    Forward   `5’-TGATGACATCAAGAAGGTGGTGAAG-3’`
           Reverse   `5’-TCCTTGGAGGCCATGTGGGCCAT-3’`

IL, interleukin; TNF, tumor necrosis factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase

Statistical analysis {#sec010}
--------------------

For each of the analyzed parameters, values were presented as mean ± standard deviation (SD). Analysis of variance (ANOVA) test followed by post-hoc analysis using Tukey's comparison test was used to compare the results of the control group with those of the TMSC, TMSC-CM, and TMSC-CM-conc group (\**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001, respectively). All statistical analyses were performed using GraphPad Prism software version 6 (GraphPad Software, Inc., La Jolla, CA, USA); a *p*-value less than 0.05 was considered statistically significant.

Results {#sec011}
=======

Effects of TMSC and TMSC-CM on splenocyte proliferation {#sec012}
-------------------------------------------------------

The rate of proliferation of splenocytes was significantly reduced by the number of TMSC and the concentration of TMSC-CM. Splenocytes stimulated by LPS or PMA/ionomycin showed a decreased proliferation rate (fold change) when co-cultured with TMSC, and cultured in TMSC-CM; the proliferation rates were 7.30 ± 0.43, 5.77 ± 0.56, 4.88 ± 0.80, 4.28 ± 0.22, 5.56 ± 0.18, and 4.45 ± 0.87 in LPS, LPS + 5×10^3^ TMSC, LPS + 5×10^4^ TMSC, LPS + 5×10^5^ TMSC, LPS + TMSC-CM, and LPS + TMSC-CM-conc, respectively (*p* \< 0.0001, ANOVA); 6.49 ± 0.13, 4.71 ± 0.06, 4.34 ± 0.83, 4.30 ± 0.30, 2.27 ± 0.33, and 2.13 ± 0.47 (stimulated by PMA/ionomycin) (*p* \< 0.0001, ANOVA) ([Fig 2](#pone.0225739.g002){ref-type="fig"}).

![Splenocyte immunosuppression assay.\
The splenocyte stimulated by LPS (A) or PMA/ionomycin (B) shows decreased proliferation rate when co-cultured with TMSC and cultured in TMSC-CM. Proliferation was significantly reduced by the number of TMSC and the concentration of TMSC-CM. (mean with standard deviation, \**p* \< 0.05, \*\*\**p* \< 0.001) LPS, lipopolysaccharide; PMA, phorbol 12-myristate 13-acetate.](pone.0225739.g002){#pone.0225739.g002}

Anti-inflammatory protein expression of TMSC-CM {#sec013}
-----------------------------------------------

Following the administration of TMSC-CM, cytokines and growth factors were highly expressed compared to the use of basal medium ([Fig 3(A)](#pone.0225739.g003){ref-type="fig"}). Proteins that were highly expressed following treatment with TMSC-CM included growth factors such as hepatocyte growth factor (HGF), placental growth factor (PIGF), and vascular endothelial growth factor (VEGF), tissue repair-related proteins including thrombospondin-1, urokinase-type plasminogen activator (uPA), and monocyte chemoattractant protein (MCP)-1, the anti-inflammatory protein transforming growth factor (TGF)-β, and the anti-apoptosis protein tissue inhibitor of metalloproteinase (TIMP)-1 ([Fig 3(B)](#pone.0225739.g003){ref-type="fig"}).

![Cytokine and angiogenesis array.\
(A) Basal medium and TMSC-CM are applied to each array membrane. (B) When administered with TMSC-CM, growth factors, tissue repair, anti-inflammatory, and anti-apoptosis proteins were highly expressed compared to when the basal medium was applied. (mean with standard deviation) O.D., optical density; HGF, hepatocyte growth factor; PIGF, placental growth factor; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; HB-EGF, heparin binding epidermal growth factor-like growth factor; uPA, urokinase-type plasminogen activator; MCP, monocyte chemoattractant protein; CXCL, C-X-C Motif chemokine ligand; SDF, stromal cell-derived factor; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; TIMP, tissue inhibitor of metalloproteinase; IGFBP, insulin-like growth factor-binding protein.](pone.0225739.g003){#pone.0225739.g003}

Protective effect of TMSC and TMSC-CM on colonic inflammation in DSS mouse model {#sec014}
--------------------------------------------------------------------------------

A total of 61 male mice were randomly assigned into 5 groups: normal control (n = 14), colitis control (n = 14), TMSC group (n = 9), TMSC-CM group (n = 14), and TMSC-CM-conc group (n = 10).

On day 30 of the experiment, DAI was significantly decreased in the TMSC, TMSC-CM, and TMSC-CM-conc groups compared to that in the colitis control group (4.44 ± 3.91, 1.80 ± 0.54, 1.54 ± 0.69, and 1.28 ± 0.67 in the colitis, TMSC, TMSC-CM, and TMSC-CM-conc group, respectively (*p* = 0.0022, ANOVA)). There were no significant differences between the DAI values for each of the treatment groups ([Fig 4](#pone.0225739.g004){ref-type="fig"}). The weight change (%) at day 30 for the TMSC, TMSC-CM, and TMSC-CM-conc groups was significantly increased compared to that of the colitis control group (-2.69 ± 19.79, 9.25 ± 6.53, 11.12 ± 12.12, and 13.57 ± 7.20, *p* = 0.0183). There were no significant differences between the weight gain (%) values for each of the treatment groups ([Fig 5](#pone.0225739.g005){ref-type="fig"}). The recovery of colon length (cm) observed at day 30 for the TMSC, TMSC-CM, and TMSC-CM-conc groups were significantly better than the recovery in the colitis control group (72.21 ± 6.55, 80.68 ± 5.87, 80.5 ± 7.05, and 81.8 ± 5.57, *p =* 0.0014). There were no significant differences between the colon length (cm) values for each of the treatment groups ([Fig 6](#pone.0225739.g006){ref-type="fig"}) ([S3 Table](#pone.0225739.s003){ref-type="supplementary-material"}). The survival rate of the colitis control group was 78.6% and 100% for the three treatment groups.

![Disease activity index (DAI).\
DAI was significantly decreased in TMSC, TMSC-CM, and TMSC-CM-conc group compared to the colitis control group at the 18th, 30th day of experiment. (mean with standard deviation, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001).](pone.0225739.g004){#pone.0225739.g004}

![Weight recovery.\
The weight recovery at the 18th, 30th day of experiment was significantly greater in TMSC, TMSC-CM, and TMSC-CM-conc groups compared to that in colitis control group. (mean with standard deviation, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001).](pone.0225739.g005){#pone.0225739.g005}

![Colon length.\
(A) Colon length at the 30th day of experiment was significantly increased in TMSC, TMSC-CM, and TMSC-CM-conc group compared to the colitis control group. (mean with standard deviation, \**p* \< 0.05, \*\**p* \< 0.01) (B) Resected colons of each group are shown.](pone.0225739.g006){#pone.0225739.g006}

Histopathological alteration {#sec015}
----------------------------

Histopathologic findings of the dissected colon specimen showed infiltration of mononuclear cells and crypt damage, but no perforation. Histologic colitis scoring assessed after H&E staining did not show any significant differences between each group (*p* = 0.2933, ANOVA) ([Fig 7](#pone.0225739.g007){ref-type="fig"}, [S4 Table](#pone.0225739.s004){ref-type="supplementary-material"}).

![Histopathological alteration.\
(A) Histologic colitis scoring did not show significant difference between each of groups. (B) Histopathologic findings of distal colon of each group are shown. (Hematoxylin-eosin (H&E) stain, 100x).](pone.0225739.g007){#pone.0225739.g007}

Cytokine levels of colon tissues treated with TMSC or TMSC-CM {#sec016}
-------------------------------------------------------------

With respect to the cytokine levels of the colon tissue, the level of the IL-1β proinflammatory cytokine was significantly lower in the TMSC, TMSC-CM, and TMSC-CM-conc groups than in the colitis control group (*p* = 0.0188, ANOVA). The IL-6 level was significantly lower in the TMSC and TMSC-CM-conc groups (*p* = 0.0103, ANOVA), and the IL-17 level was significantly lower in the TMSC-CM and TMSC-CM-conc groups (*p* = 0.0456, ANOVA) than in the colitis control group. There were no significant differences between the cytokine levels in each of the treatment groups. There were no significant differences between the expression levels of TNFα (*p* = 0.1611, ANOVA) and IL-10 (*p* = 0.4506, ANOVA) in each group ([Fig 8](#pone.0225739.g008){ref-type="fig"}, [S5 Table](#pone.0225739.s005){ref-type="supplementary-material"}).

![Cytokine levels of colon tissue.\
The level of IL-1β was significantly lower in TMSC, TMSC-CM, and TMSC-CM-conc groups compared to the colitis control group. (mean with standard deviation, \**p* \< 0.05, \*\**p* \< 0.01) IL, interleukin; TNF, tumor necrosis factor.](pone.0225739.g008){#pone.0225739.g008}

Discussion {#sec017}
==========

To the best of our knowledge, this is the first study to evaluate the therapeutic effect of TMSC-CM in a chronic colitis mouse model. It is clinically meaningful that the effect of TMSC and TMSC-CM are similar, because TMSC-CM is easier to prepare and administer to patients. In addition, the amount of TMSC-CM used in this study included fewer cells compared to the TMSC group, whereas the therapeutic effects were similar, suggesting that the therapeutic effect of TMSC-CM is clinically significant.

Many previous reports have reported the therapeutic effects of MSC for colitis. When human adipose-derived MSC (ASC) were IP injected in the DSS-induced acute and chronic colitis mouse models, histopathological severity of colitis, weight loss, diarrhea, inflammation, and survival rates improved, and ASC were reported to decrease inflammatory cytokine levels and correlated with the induction of IL-10-secreting T regulatory cells \[[@pone.0225739.ref023]\]. Another study demonstrated that the IP injection of nucleotide-binding oligomerization domain 2 (NOD2)-activated human umbilical cord blood (UCB) MSC into DSS or trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse models resulted in the decreased severity of colitis and increased anti-inflammatory responses such as expression of IL-10 and T regulatory cells \[[@pone.0225739.ref015]\]. The IP injection of bone marrow-derived MSC (BM-MSC) into DSS-induced acute colitis models resulted in the reduction of colitis and recovery of body weight associated with TNFα-stimulated gene-6, an important immunoregulatory molecule \[[@pone.0225739.ref024]\]. In the present study, the TMSC injection group showed improvements in severity of colitis, weight loss, and colon length compared to the control group, and levels of proinflammatory cytokines including IL-1β and IL-6 were low, similar to the results of previous studies which assessed the effect of MSC.

The effect of MSC-CM has not been investigated thoroughly compared to the effect of the MSC injection itself. In a previous study using an acute colitis model, human BM-MSC and BM-MSC-CM were each administered by enema to TNBS-induced acute colitis guinea pig models with enteric neuropathy and motility dysfunction. Both treatment groups showed improvements in weight loss and gross morphological, and histological colon damage, with the prevention of loss of myenteric neuron and nerve process damage, compared to the colitis control group. There was no significant difference between BM-MSC- and BM-MSC-CM-treated groups \[[@pone.0225739.ref025]\]. In another study using human amnion-derived MSC, MSC were intravenously injected and MSC-CM was administered via enema to TNBS-induced acute colitis rat models. Both groups showed significant improvements in the endoscopic score and decreased infiltration of neutrophils, monocytes, macrophages, TNF-α, C-X-C Motif chemokine ligand 1 (CXCL1), and C-C motif chemokine ligand 2 (CCL2) \[[@pone.0225739.ref026]\]. In the present study, we evaluated the effect of TMSC-CM in a chronic colitis model induced by DSS, which is more similar model to human IBD, which features chronic relapsing and remitting episodes.

The similar effects of MSC and MSC-CM support the concept that MSC themselves does not migrate and act on the target, but rather that the substances that the cells secrete such as extracellular vesicles (EVs) or soluble proteins, contribute to the treatment effect. In a study in which BM-MSC were IP injected into a DSS-induced acute colitis animal model and BM-MSC were simultaneously tracked, aggregation was observed mostly with macrophages, B cells, and T cells, and were located in the peritoneal cavity, whereas fewer than 1% reached the inflamed colon \[[@pone.0225739.ref024]\]. MSC did not migrate directly to the colon, but decreased colitis was observed. It has also been reported that when MSC-CM is applied to hypoxic-damaged cardiomyocytes, it protects cardiomyocytes by the paracrine effect, which interferes with mitochondria-mediated apoptosis \[[@pone.0225739.ref027]\]. However, some studies have demonstrated that the injected MSC move directly towards the target. In a study conducted in a rat model with calvarial bone defect, fluorescent-labeled rat MSC were injected into the caudal vein and graft material made from BM-MSC-CM was applied to the lesion. The MSC gradually migrated to the defect site \[[@pone.0225739.ref028]\]. In an acute pancreatitis rat model, fluorescent-labeled BM-MSC were injected and it migrated to the damaged site of the pancreas \[[@pone.0225739.ref029]\]. Therefore, further studies are necessary to elucidate MSC migration according to the disease model.

Recently, MSC-derived EVs have been reported to be effective through cell-to-cell communication, cell signaling, and altering cell or tissue metabolism in the body \[[@pone.0225739.ref030]\]. In addition, several reports have suggested that EVs may be used for treatment as a substitute for cell therapy \[[@pone.0225739.ref031]--[@pone.0225739.ref034]\]. Intramyocardial injection of EVs sourced from human BM-MSC into rats with acute myocardial infarction reduced the infarct size and improved cardiac function \[[@pone.0225739.ref035]\]. Intravenous (IV) injection of exosomes obtained from human UCB MSC into acute lung injury mice resulted in the suppression of hypoxic inflammation \[[@pone.0225739.ref036]\]. In a skin second-degree burn wound rat model, human UCB MSC exosomes were injected subcutaneously and resulted in wound healing due to increased re-epithelialization \[[@pone.0225739.ref037]\]. Periocular injection of MSC exosomes in an autoimmune uveitis rat model reduced infiltration in T cells and other inflammatory cells, and eventually improved uveitis \[[@pone.0225739.ref038]\]. In this study, because TMSC-CM were filtered using a 0.2 μm filter, only EVs with diameters less than 200 nm were extracted from the TMSC-CM. After centrifugation with a 100 kDa cut-off filter, only the upper tube substrates heavier than 100 kDa were selected, which can be converted to particles with a diameter of 10 nm or larger. Since the diameter of the exosome generally ranges from 30 to 100 nm \[[@pone.0225739.ref039]\], the particle size range of 10 to 200 nm in this study would have contained a slightly wider range of exosomes. Therefore, the exosomes in TMSC-CM may have induced therapeutic effects in chronic colitis, which is consistent with results of previous studies. However, in our previous attempt, the lower tube materials weighing less than 100 kDa which were produced after co-culturing with PMA/ionomycin-stimulated splenocytes also showed therapeutic effects. Therefore, it is necessary to conduct repetitive experiments using EVs in each weight range to specifically evaluate their influence.

Collectively, these results support the view that administering MSC themselves and only MSC-CM results in equivalent therapeutic effects, which may support the application of MSC-CM over cell transplantation. This application is desirable, because it would be easier to perform and would also be accompanied with fewer side effects. Additionally, MSC-CM was simpler to prepare and store than MSC during the experiment; therefore, MSC-CM would be more feasible for clinical applications. In contrast to other MSC, TMSC differentiate into the endoderm as well as the mesoderm, and are readily and inexpensively available, as they can be acquired from tonsillectomy surgeries, which are commonly performed in children. They also have shorter doubling time because of the young age of the donors. These factors may make TMSC superior to other MSC in many aspects \[[@pone.0225739.ref018]\]. Therefore, the development and application of a TMSC-CM-derived therapeutic agent for IBD treatment would be highly effective and clinically feasible.

There were several limitations to this study. First, TMSC and TMSC-CM were injected through the IP route. For clinical applications, the drug should be delivered either intravenously or transanally. In a previous attempt by us, TMSC administration via IV injection and transanal enema were also attempted. These were not as effective as IP injection, possibly owing to the difficulty of IV administration through the tail vein of the mouse, which creates a stressful environment for the mouse. When transanal enema was attempted, most of the liquid leaked out of the anus just after the enema, which resulted in insignificant effects. Secondly, the injected amount of TMSC or TMSC-CM for each injection was high. Generally, the appropriate injection amount for IP injection in a mouse model is 20 to 80 mL/kg \[[@pone.0225739.ref040]\]; in this study the average weight of the mouse was 20 to 22g. Therefore, the appropriate injection amount was 400 to 1600 μL per injection. Considering that weight loss represents the induction of chronic colitis, 500 μL was injected. However, this amount is excessive when considering human injection dosage. Therefore, it is necessary to concentrate the injectate as much as possible and reduce the amount in single doses, within the range that the solution does not solidify. Thirdly, the histological colitis scoring system was used for histologically comparing the H&E-stained specimen, which showed no significant findings. The scores obtained using the histological scoring system showed a significant difference between the treatment and colitis control groups in a previous study conducted using the acute colitis mouse model, in which colitis was induced for 7 days. However, in the current study using the chronic colitis model, in which colitis was induced for 30 days, it seems that the healing was not reflected in the scoring system because of the fibrotic change, resulting in no significant difference between the groups. Additional analysis regarding other histologic scoring systems should be performed. In addition, other staining methods such as Masson's trichrome staining should be performed to evaluate the distribution of the collagen fibers, which is related to chronic inflammation and fibrosis.

Conclusion {#sec018}
==========

TMSC-CM showed effects that were equivalent to those of TMSC on reducing inflammation in a DSS-induced chronic colitis model. Therefore, it is expected that administration of TMSC-CM, and not the TMSC themselves, may exert a therapeutic effect in IBD. Preparing and storing of TMSC-CM is clinically more feasible than compared to TMSC. Therefore, TMSC-CM could serve as a good therapeutic agent to treat IBD.

Supporting information {#sec019}
======================
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Reviewer \#1: The idea of using the secretome of MSCs to treat an inflammatory disease is appropriate. However, the data do not support the conclusion. It appears that the MSC treatment was more superior to than the secretome. The condition media used a cut off that could consist of secretome other than cytokines. The CM used was from naive MSCs. It is possible when these cells are in an inflammatory environment the secretome will be different.

-\> We thank the reviewer for their comments. The TMSC cells were cultured in low-glucose Dulbecco's modified Eagle's medium (DMEM) containing antibiotics and 10% heat-inactivated fetal bovine serum (FBS), until they attained a cell density of 5×105 cells/well. TMSC conditioned medium (TMSC-CM) was acquired after seeding 5×105 TMSC (in 10ml low-glucose DMEM containing 10% FBS) in a 100 mm dish and harvesting from the cells for 5--7 days (total 2×106 cells). Therefore, TMSC and TMSC-CM were both acquired from non-inflammatory environments. \[Materials and Methods section; page 6-7\].

The TMSC-CM group received 12 IP injections of 500 μL of TMSC-CM (equivalent to 1×105 TMSC) in order to match the amount of TMSC administered with the TMSC group. As the number of injections increases, the injection-related stress of the mouse increases. Therefore, the same number of injections was used to reduce the bias. Consequently, the triple-concentrated (using a 100 kDa cut-off centrifugal filter) TMSC-CM-conc group, which received four IP injections of 500 μL of TMSC-CM-conc (equivalent to 3×105 TMSC) was set up so that the number of injections would be equivalent to that of the TMSC group. \[Materials and Methods section; page 7, 9\].

In our results, DAI values, weight change, and recovery of colon length were improved in the TMSC, TMSC-CM and TMSC-CM-conc groups compared to that of the colitis control group. However, there were no significant differences between the DAI values, weight change and recovery of colon length for each of the three treatment groups. \[Results section; page 15\].

Reviewer \#2: In the manuscript entitled "The Efficacy of Conditioned Medium Released by Tonsil-derived Mesenchymal Stem Cells in a Chronic Murine Colitis Model" the authors describe a new approach to treat chronic colitis by means of tonsil-derived mesenchymal stem cells (TMSC) in a mouse model of chronic colitis.

The authors have shown the efficacy of tonsil-derived mesenchymal stem cells conditioned medium (TMSC-CM) in the control of this inflammatory bowel disease clinical and immunological parameters but not of the histological colitis score.

The authors underline that the preparation and storing of TMSC-CM is clinically more feasible respect to TMSC isolation and suggest that TMSC-CM therapy could serve as a pharmacological agent to treat chronic colitis.

In my opinion these data are interesting and deserve publication on PlosOne. I suggest however that the authors discuss further the lack of histological score improvement and explain better the scheme of treatments in particular the higher quantity of injections in the TMSC-CM mouse group (12 respect to 4).

-\> Thank you for your valuable comments.

1\) We have now inserted the results of the histologic findings in the results section. \[Results section; page 16\].

"Histopathologic findings of the dissected colon specimen showed infiltration of mononuclear cells and crypt damage. Histologic colitis scoring, assessed after H&E staining, did not show any significant differences between each group (p = 0.2933, ANOVA) (Fig. 7)."

We have now discussed the reasons, as suggested, in the discussion section. \[Discussion section; page 22\].

"The scores obtained using the histological scoring system showed a significant difference between the treatment and colitis control groups in a previous study conducted using the acute colitis mouse model, in which colitis was induced for 7 days. However, in the current study using the chronic colitis model, in which colitis was induced for 30 days, it seems that the healing was not reflected in the scoring system because of the fibrotic change, resulting in no significant difference between the groups. Additional analysis regarding other histologic scoring systems should be performed. In addition, other staining methods such as Masson's trichrome staining should be performed to evaluate the distribution of the collagen fibers, which is related to chronic inflammation and fibrosis."

2\) The TMSC-CM group received 12 IP injections of 500 μL of TMSC-CM (equivalent to 1×105 TMSC) in order to match the amount of TMSC administered with the TMSC group. As the number of injections increases, the injection-related stress of the mouse increases. Therefore, the same number of injections was used to reduce the bias. Consequently, the triple-concentrated (using a 100 kDa cut-off centrifugal filter) TMSC-CM-conc group, which received four IP injections of 500 μL of TMSC-CM-conc (equivalent to 3×105 TMSC) was set up so that the number of injections would be equivalent to that of the TMSC group. \[Materials and Methods section; page 7, 9\]. We have now modified figure 1, as requested. \[Fig 1.\]

Grammar and style should also be improved.

-\> This work has now been further professionally edited for English content, as requested, and we attach the certificate.

Reviewer \#3: Minor English wording and syntax changes are necessary. Otherwise, it is a very good paper an provides a ready means for MSC and their products in immunotherapy

-\> We thank the reviewer for their comments. This work has now been further professionally edited for English content, as requested, and we attach the certificate.

Reviewer \#4: The manuscript by Ko Eun Lee, Sung-Ae Jung et al. describes the development of the approach to reduce an inflammation in the chronic colitis using a conditioning media from a human tonsil-derived mesenchymal stem cells (TMSC). Authors are already published several papers regarding the injection of TMSCs in order to treat colitis in mice models. However, they found that TMSC cells are not migrated to the inflammation site in the intestine, therefore in the current manuscript they validated the conditioned media from the TMSCs.

They found that the CM can change the disease progression like cells itself.

Authors utilized a well-established mouse model using DSS (dextran sulfate sodium) to induce the chronic and acute colitis. The assessment of the severity disease is well-established, and authors employed these parameters in they work (weight of mice, the colon length, levels of proinflammatory cytokines).

Major specific comments:

1\) The rate of splenocytes was reduced (p13), but this section causes the confusion. Proliferation rates was measured in what (days)? Fig. 2 presents the folds changes. Please clarify.

-\> In the bar graph of Fig 2, the rate of proliferation of splenocytes stimulated by LPS only showed an increase in proliferation rate (fold change). However, when the splenocytes were co-cultured with TMSC or TMSC-CM in the presence of LPS, there was a decreased proliferation rate (fold change). \[Results section; page 13\].

2\) It is understandable that the TMSC-CM causes the protective anti-inflammatory effect on the colonic inflammation. However, it is raising the question can this therapy impact on a mice immuno system causing the immunogenicity and other complications?

-\> We thank the reviewer for their comments. When we evaluated the dissected colon specimen from sacrificed mice, they showed reduction of colon length and inflammation but no perforation. This information has now been added to the Results section. \[Results section; page 16\].

As this is the result of an in vitro study, it is possible that TMSC-CM may affect inflammatory and anti-inflammatory cytokines and therefore may alter the immune system. However, further in vitro study will be needed to evaluate the immunological mechanisms. \[Results section; page 13-14\].

3\) How long after this treatment mice can survive compare with the disease bearing group?

-\> In this study, we sacrificed mice with CO2 inhalation on day 31, so we did not assess how long the treated mice could survive for. The mice that died during the 30 day experiment died because of weight loss during the second inducing period of 1.5% DSS. After that period, the mice generally survived. This information has now been added to the Materials and Methods section. \[Methods section; page 10\].

4\) p.15 Fig. 4, Disease activity index (DAI) was define in the legend, please do it in the page 10, since it appears early.

-\> "Disease activity index (DAI)" was mentioned and defined in the 'Introduction section' (page 5). Therefore, in accordance with the journal guidelines, further description was not needed in the Method section (page 10). \[Introduction section; page 5\].

5\) Fig. 3 will be better if both panels are presented on the same page.

-\> As suggested, panel B has now been moved to underneath panel A, in Fig. 3.

6\) Fig. 4 does not have panels, but 4 graphs are presented.

-\> We have now inserted the panel names of (A), (B), (C) and (D), and modified part of Fig. 4.

7\) Fig. 5 does not have panels, but 4 graphs are presented.

-\> We have now inserted the panel names of (A), (B), (C) and (D), and modified part of Fig. 5.

8\) Fig. 8 legend (p16.-17), it is not quite understood where words on p. 17 belong.

-\> We have now changed the location of the legend to Fig. 8. This is now displayed on one side of the paper.

9\) Are the bars are presented with SD or SE.

-\> The error bars of all graphs show standard deviation (SD), and this description has now been added to all figure legends.

It is a plus for the manuscript that authors define all limitations of the approach at the end of the manuscript. It is a good piece of the work which is required further validations and exploration.
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